4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 10% – Still a Buy?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s share price rose 10% during mid-day trading on Monday . The stock traded as high as $13.15 and last traded at $13.4030. 182,547 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 783,342 shares. The stock had previously closed at $12.19.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on FDMT shares. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. B. Riley Financial started coverage on shares of 4D Molecular Therapeutics in a research report on Friday, July 31st. They issued a “buy” rating and a $37.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Finally, Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.62.

4D Molecular Therapeutics Price Performance

The company’s 50-day simple moving average is $10.94 and its 200 day simple moving average is $9.89. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $730.82 million, a price-to-earnings ratio of -5.34 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The company had revenue of $3.78 million for the quarter, compared to the consensus estimate of $3.62 million. Equities research analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current year.

Insiders Place Their Bets

In related news, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider owned 942,485 shares in the company, valued at $9,867,817.95. This trade represents a 10.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. This represents a 53.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 197,226 shares of company stock worth $2,200,677 over the last quarter. 7.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FDMT. Legal & General Group Plc acquired a new stake in 4D Molecular Therapeutics during the second quarter worth about $59,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics during the 3rd quarter valued at about $41,000. Daiwa Securities Group Inc. increased its holdings in shares of 4D Molecular Therapeutics by 3,362.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after buying an additional 6,186 shares in the last quarter. Susquehanna Portfolio Strategies LLC acquired a new position in shares of 4D Molecular Therapeutics in the 4th quarter worth approximately $77,000. Finally, Martingale Asset Management L P raised its position in 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock valued at $88,000 after purchasing an additional 1,303 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.